Van Tıp Dergisi (May 2020)
The Frequency of Factor V Leiden in Type 2 Diabetic Patients
Abstract
INTRODUCTION: Diabetes mellitus, a multifactorial and polygenic disease, is a major health problem worldwide. An increased risk for the development of thromboembolic and atherosclerotic diseases has been reported in diabetic patients with Factor V Leiden (FVL) mutation. Therefore, we think that it is important to detect diabetic patients with genetic polymorphism. The aim of our study was to investigate the frequency of FVL mutation in patients with diabetes mellitus. METHODS: This study included 67 patients with diabetes mellitus. FVL mutation was investigated in all patients. The SNaPshot® multiplex system (Applied Biosystems Inc. Switzerland) was used. The heterozygous and homozygous genotypic distributions and percentages were determined. RESULTS: There were 37 females and 30 males, ranging in age from 32 to 88 years with a mean age of 61.6 +- 11.1 years. There were no patients with homozygous FVL mutation. The heterozygous FVL mutation was detected in eight patients (11.9%). Of these eight patients with FVL mutation, five (62.5%) had hypertension, four (50%) had asymptomatic peripheral artery disease, and one (12.5%) had coronary artery disease. DISCUSSION AND CONCLUSION: Although the frequency of FVL mutation is not high in diabetic patients; thromboprophylaxis should be performed in diabetic patients in risky conditions such as surgery, long-term bed rest or trauma.
Keywords